Insulet Stock - Citi trims price target after Q1 beat
18.06.2026 - 18:19:08 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 17:17 UTC. Details in the imprint.
Insulet (US45784P1012) remains in analysts’ crosshairs after a fresh target cut from Citi. The US medtech group recently reported Q1 2026 results that exceeded expectations, prompting Wall Street to revisit its models according to a Seeking Alpha-based summary.
All news and analysis on Insulet stock
Key figures, analyst opinions and regulatory filings on Insulet are bundled in our topic section for readers who want to track the stock more closely.
What Citi changed on Insulet
Citi lowered its price target on Insulet shares to $165 from $175 and maintained a Neutral rating, according to a summary of post-earnings analyst actions based on Seeking Alpha data. Intellectia cites this update in a note on Insulet’s Q1.
The bank adjusted its models as part of a broader review of the medical technology space after first-quarter reports across the sector, signaling a more cautious stance on valuation despite solid fundamentals mentioned for medtech names.
Q1 2026 performance and context
Insulet reported Q1 2026 results that exceeded market expectations, according to the same analyst summary, although detailed revenue and EPS figures were not highlighted in that note. The Intellectia overview points to a Q1 beat versus consensus.
Citi nevertheless reduced the target, illustrating that even earnings beats do not automatically translate into higher fair-value estimates when valuation, competitive dynamics or risk assessments shift across a sector.
How Insulet sits in analyst consensus
Beyond Citi, Insulet remains widely covered on Wall Street as a growth-oriented diabetes technology name on the Nasdaq. Consensus data from market aggregators in mid-2026 generally show a mix of Buy and Hold ratings, with only a small minority at Sell.
Average price targets from recent months have tended to sit above the current market price, implying upside from a purely arithmetic standpoint, yet the dispersion of targets is meaningful and reflects differing views on insulin pump competition and reimbursement trends.
Recent share price snapshot
On Thursday, Insulet shares traded around $145 on Nasdaq by late morning Eastern time, according to a real-time quote snapshot. MarketBeat listed the stock at $145.04, up about 1.1% intraday.
This quote implies that Citi’s $165 target still sits moderately above the current level, but with far less implied appreciation than earlier, underscoring the house’s more measured stance on near-term risk-reward.
The product behind the stock
Insulet generates most of its revenue from its Omnipod family of insulin delivery systems, a tubeless wearable insulin pump platform for people with diabetes. The business model combines ongoing pod sales with associated technology and software support for patients and caregivers.
Where the stock trades today
Insulet shares (US45784P1012) trade on Nasdaq at approximately $145.04 as of 06/18/2026, 11:30 ET.
Key facts on Insulet stock
- Company: Insulet Corp.
- ISIN: US45784P1012
- WKN: A0LCB0
- Ticker: PODD
- Venue: Nasdaq
- Price (as of 06/18/2026, 11:30 ET): 145.04 USD
- Market cap: approximately 9.4 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
